Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Michael J. Fox Foundation (MJFF) has awarded funds to NeuroPhage Pharmaceuticals to conduct pre-clinical research targeting alpha-synuclein.
Subscribe to our email newsletter
Alpha-synuclein is a protein whose clumping is the pathological sign of Parkinson’s disease (PD).
NeuroPhage Preclinical R&D senior vice president Kimberley S Gannon said the grant will provide NeuroPhage with access to world class experts in PD and they look forward to a productive relationship with MJFF.
NeuroPhage will evaluate the effect of NPT001, a novel therapeutic in development for Alzheimer’s disease on alpha-synuclein levels in a pre-clinical model of PD.
In preliminary preclinical studies, NPT001 has been found to reduce brain levels of alpha-synuclein.
MJFF Research programs associate director Kuldip Dave said alpha-synuclein is a high-priority target for the foundation, as there is evidence that it may play a role in both genetic and idiopathic cases of PD.
"NeuroPhage’s unique approach has the potential to reduce levels of alpha-synuclein in the brain, which could, in turn, lead to novel therapies to treat PD," Dave added.